Technological Innovations and Growing Adoption of Decentralized Testing to Drive Point of Care Infectious Disease Diagnostics Market to USD 17,633.5 Mn by 2033 at 14.7% CAGR – Coherent Market Insights
The global point of care infectious disease diagnostics market by Technology (Lateral Flow, Agglutination Assays, Flow-Through, and Solid Phase), By Application (HIV, Tropical Disease, Liver Disease, Inflammatory Disease, Respiratory Disease, Hospital Associated Infections (HAIs), Sexual Health Disorders, and Others), By End User (Hospitals, Diagnostic Laboratories, Home-Care Settings, and Others), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at USD 6,834.4 Mn in 2026 and is projected to exhibit a CAGR of 14.7% over the forecast period (2026 – 2033). Point of care diagnostics are efficient in emerging economies of Asia Pacific wherein infectious diseases and especially tropical disease such as malaria are highly prevalent. Infectious point of care testing serves advantages such as increasing access to care in remote areas, time and cost efficiency, and rapid diagnosis, which can greatly affect treatment outcome. Infectious diseases such as HIV, tuberculosis, and malaria are prevalent in emerging economies such as Africa and Asia Pacific. For instance, according to the World Health Organization (WHO), an estimated 36.7 million people were suffering from HIV in 2016.
Market Driver
-
Rising Demand for Rapid and Decentralized Infectious Disease Testing Drives Market Growth
The Point-of-Care Infectious Disease Diagnostics Market is driven by the growing need for rapid, accurate testing near patients, enabling healthcare providers to initiate treatment sooner and reduce disease transmission. Portable molecular systems, multiplex assays, simplified sample preparation, and battery-powered devices are expanding diagnostic access across clinics, emergency departments, community health centres, and resource-limited settings.
For instance, in March 2026, the World Health Organization recommended new near-point-of-care tuberculosis tests capable of operating on battery power and producing results in under one hour. WHO stated that these tests cost less than half as much as many existing molecular diagnostic systems and may also support testing for HIV, mpox, and HPV. This recommendation is expected to accelerate the adoption of affordable, multi-disease point-of-care platforms globally.
Additionally, the U.S. FDA cleared the VELO Respiratory Test in February 2026, providing multiplex RT-PCR detection of SARS-CoV-2, influenza A, and influenza B within ten minutes. (Source: WHO; FDA)
Market Opportunity
-
Expansion of Affordable, Multi-Disease Testing in Underserved Regions Creates Market Opportunity
A major opportunity in the Point-of-Care Infectious Disease Diagnostics Market lies in deploying affordable molecular testing platforms across community clinics, mobile units and healthcare facilities with limited laboratory infrastructure. Demand is particularly strong in low- and middle-income countries, where more than 80% of global tuberculosis cases and deaths occur.
For instance, in March 2026, the World Health Organization recommended a new class of near-point-of-care nucleic acid amplification tests for tuberculosis. These battery-operated systems can deliver results in less than one hour, require limited technical skills and cost approximately half as much as existing laboratory-based molecular tests. WHO also highlighted their potential use for HIV, mpox and HPV testing, creating opportunities for manufacturers to develop portable, multiplex platforms that support several infectious-disease programmes through a single testing system. (Source: WHO)
Market Trends
-
Rising Adoption of Ultra-Rapid Multiplex RT-PCR Systems
Manufacturers are developing compact molecular systems that combine laboratory-level PCR performance with turnaround times of only a few minutes. In April 2026, QuidelOrtho completed its approximately USD 100 million acquisition of LEX Diagnostics. The acquired VELO Respiratory Test received FDA clearance and a CLIA waiver in February 2026 and can detect influenza A, influenza B, and SARS-CoV-2 in approximately six to ten minutes. (Source: QuidelOrtho Corporation)
-
Increasing Deployment Across Urgent-Care Networks
Healthcare providers are moving infectious disease testing from centralized laboratories into urgent-care centres and outpatient clinics. In June 2026, Lumos Diagnostics announced the rollout of its FebriDx point-of-care test across 43 additional WellStreet urgent-care locations in the United States. FebriDx uses a fingerstick blood sample to help differentiate bacterial from non-bacterial respiratory infections, supporting more targeted treatment decisions.
-
Expansion of Multiplex Testing Beyond Respiratory Infections
Point-of-care molecular testing is expanding into women’s health and genital infections, allowing several pathogens to be identified during a single patient visit. For instance, in June 2026, bioMérieux submitted dual FDA 510(k) and CLIA-waiver applications for its BIOFIRE SPOTFIRE Vaginitis Panel. The development indicates growing investment in rapid syndromic panels for decentralized healthcare settings. (Source: bioMérieux)
-
Growing Demand for Portable and Affordable TB Diagnostics
Battery-operated molecular platforms are gaining importance in regions with limited laboratory infrastructure. In March 2026, the World Health Organization issued its first recommendations for near-point-of-care molecular tuberculosis tests. These portable tests can produce results in under one hour, require limited technical expertise, and are available at less than half the cost of many existing molecular diagnostic systems, supporting wider testing in underserved communities. (Source: WHO)
To know the latest trends and insights prevalent in the Point of Care Infectious Disease Diagnostics Market, click the link below:
Key Takeaways of the Point of Care Infectious Disease Diagnostics Market
- The global point of care infectious disease diagnostics market is expected to exhibit a CAGR of 14.7% over the forecast period (2026 – 2033), owing to product launches by the key players such as Alere, Inc., and rising demand for rapid diagnostic tests
- Hospital associated infections (HAIs) is expected to exhibit strong growth and is expected to generate maximum revenue over the forecast period
- Major players operating in the point of care infectious disease diagnostics market include Danaher Corporation, Abbott Laboratories, Acon Laboratories, Inc., Hoffman-La Roche Ltd., Becton, Dickinson, and Company, Trinity Biotech Plc, AccuBioTech Co., Ltd. and Cardinal Health, Inc.
Contact Us